AM Pharma and Pfizer, committed to addressing the high unmet medical need in Acute Kidney Injury.




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: AM Pharma and Pfizer, committed to addressing the high unmet medical need in Acute Kidney Injury.
Released on: May 28, 2015. © PTV
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Depending on the severity of kidney failure, the mortality rate ranges from 7% to as high as 80%, with an average rate of approximately 35%.
  • Summary
  • Transcript
  • Participants
  • Company
Depending on the severity of kidney failure, the mortality rate ranges from 7% to as high as 80%, with an average rate of approximately 35%. Erik van den Berg, CEO of AM-Pharma tells PharmaVentures' CEO, Fintan Walton why this agreement is a significant step, not only for AM-Pharma and Pfizer, but also to the development of a potential treatment for Acute Kidney Injury and other inflammatory diseases.
Depending on the severity of kidney failure, the mortality rate ranges from 7% to as high as 80%, with an average rate of approximately 35%. Erik van den Berg, CEO of AM-Pharma tells PharmaVentures' CEO, Fintan Walton why this agreement is a significant step, not only for AM-Pharma and Pfizer, but also to the development of a potential treatment for Acute Kidney Injury and other inflammatory diseases.
Depending on the severity of kidney failure, the mortality rate ranges from 7% to as high as 80%, with an average rate of approximately 35%. Erik van den Berg, CEO of AM-Pharma tells PharmaVentures' CEO, Fintan Walton why this agreement is a significant step, not only for AM-Pharma and Pfizer, but also to the development of a potential treatment for Acute Kidney Injury and other inflammatory diseases.
Depending on the severity of kidney failure, the mortality rate ranges from 7% to as high as 80%, with an average rate of approximately 35%. Erik van den Berg, CEO of AM-Pharma tells PharmaVentures' CEO, Fintan Walton why this agreement is a significant step, not only for AM-Pharma and Pfizer, but also to the development of a potential treatment for Acute Kidney Injury and other inflammatory diseases.